This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Malignant neoplasm of renal pelvis신우의 악성신생물 (신우암)

A. Classification codes C65 — Malignant neoplasm of renal pelvis (part of upper urinary tract transitional cell carcinoma; includes renal pelvis–ureter tumors)
B. Synonyms Transitional cell carcinoma of the renal pelvis, Urothelial carcinoma of the renal pelvis, Upper Tract Urothelial Carcinoma (UTUC), squamous cell carcinoma of the renal pelvis
C. Adult onset Very high — occurs mainly in the 60s–70s. Three times more common in men than in women. Strongly associated with Lynch syndrome (mismatch repair defects). High incidence in areas with aristolochic acid exposure (Taiwan, the Balkans, etc.).
Special Copayment Reduction: V193 | 5 years from the date of cancer patient registration | copayment 5%

Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

Urothelial carcinoma of the renal pelvis (UTUC) is collectively referred to, together with ureteral cancer (C66), as upper tract urothelial carcinoma. The first reports of malignant tumors of the renal pelvis were made in the late 19th century, and in 1895 Trunecek was the first to describe a clinical case of transitional cell carcinoma of the renal pelvis in detail. Subsequently, in the early 20th century, before ureteroscopy technology existed, the diagnosis of renal pelvic tumors relied mainly on urine cytology and intravenous pyelography (IVP).

A notable feature of UTUC epidemiology is its association with Balkan endemic nephropathy. Specifically high UTUC incidence was reported in rural areas of the Balkans such as Yugoslavia, Romania, Bulgaria and Croatia, and after long investigation it was confirmed around 2012 that aristolochic acid (AA), which occurs naturally in soil and plants, is the cause of kidney damage and UTUC in this region. Aristolochic acid also derives from Aristolochia plants that were used as herbal medicines, and related UTUC has been reported in countries that use traditional herbal medicine, such as Taiwan, China and Korea.

The association between Lynch syndrome and UTUC was elucidated in the 1980s–90s, and it was established that MLH1 and MSH2 mutations increase the risk of UTUC 40–75-fold in addition to colorectal cancer. Today, the diagnosis and treatment of UTUC have become more precise with advances in ureteroscopy, CT urography, fluorescence in situ hybridization (FISH)–based urine cytology and endoscopic biopsy.

2. Causes

The main risk factors for UTUC largely overlap with those for bladder cancer. Smoking is the most important risk factor for UTUC, increasing UTUC risk 2.5–7-fold in smokers compared with nonsmokers. A dose-response relationship proportional to the amount and duration of smoking has been established. Aromatic amines: exposure to aromatic amines (β-naphthylamine, benzidine, etc.) among workers in the dye, rubber, leather and chemical industries increases UTUC risk.

Exposure to aristolochic acid (AA) is a highly distinctive risk factor; AA-DNA adducts induce TP53 mutations (A:T→T:A transversions) in the renal pelvic epithelium. The risk of UTUC is markedly increased in patients with aristolochic acid nephropathy. In Korea, too, UTUC cases due to the use of Aristolochia herbal medicines (madouling, guanmutong, etc.) have been reported, and herbal medicines containing aristolochic acid have been banned in Korea since 2005. Lynch syndrome (MMR gene defects) is an important hereditary risk factor for UTUC. Chronic urinary tract infection, stones and parasitic infection (schistosomiasis) are also associated with UTUC in some regions. Long-term phenacetin use (analgesic nephropathy) is also a risk factor.

3. Genetics

The molecular genetic features of UTUC partly overlap with those of urothelial carcinoma of the bladder but differ distinctly. FGFR3 mutations are found in 50–60% of UTUC, a higher frequency than in bladder cancer (30%). FGFR3 mutations are mainly associated with low-grade papillary tumors and are therapeutic targets of FGFR inhibitors (erdafitinib, dabogratinib/TYRA-300, etc.). HRAS mutations are also observed at a higher frequency than in bladder cancer.

In Lynch syndrome–associated UTUC, microsatellite instability (MSI-H) due to defects in MMR genes (MLH1, MSH2, MSH6, PMS2) is identified. MSI-H UTUC responds well to immune checkpoint inhibitors (pembrolizumab) and serves as a clue to the diagnosis of Lynch syndrome. ARID1A mutations (a component of the SWI/SNF complex) are observed in UTUC at a somewhat lower frequency than in bladder cancer. TERT promoter mutations are relatively less common in UTUC than in bladder cancer. In aristolochic acid–associated UTUC, TP53 mutations (A:T→T:A type) are characteristic, and this mutational signature serves as a fingerprint of AA exposure. Pharmacogenomically, identifying FGFR3 mutations is key to using FGFR inhibitors, and identifying MSI-H is key to choosing immune checkpoint inhibitors.

4. General epidemiology

UTUC accounts for 5–10% of all urothelial carcinomas and is much rarer than bladder cancer. Worldwide, about 2 cases per million population occur each year. The ratio of renal pelvic cancer (C65) to ureteral cancer (C66) is about 2:1. Geographic variation in incidence is large, with exceptionally high incidence reported in the Balkans and Taiwan. In Taiwan, UTUC accounts for about 30% of all urothelial carcinomas, the highest proportion in the world, which is related to past widespread use of herbal medicines containing aristolochic acid.

In Korea, aristolochic acid exposure has been reported in some regions and among users of traditional herbal medicine, and related UTUC cases are documented in the medical literature. Incidence is three times higher in men than in women and is concentrated in the 60s–70s. In Lynch syndrome carriers, the lifetime risk of UTUC reaches 40–75% with MSH2 mutations. Incidence is higher in socioeconomically vulnerable groups with high rates of smoking and occupational exposure. Because bladder cancer accompanies UTUC at diagnosis or later in about 17% of patients, periodic cystoscopic follow-up is needed.

5. Pathophysiology

The pathogenesis of UTUC follows a process of urothelial carcinogenesis similar to that of bladder urothelial carcinoma. The key is that ultimate carcinogens form adducts with urothelial cell DNA and induce mutations. In particular, N-butyl-N-(4-hydroxybutyl)nitrosamine (NNK) from smoking and hydroxylamine adducts from aromatic amines cause TP53 and FGFR3 mutations. Aristolochic acid specifically forms aristolactam-DNA adducts that induce A:T→T:A transversions in TP53, which is the unique mutational signature of aristolochic acid–associated UTUC.

In Lynch syndrome, MMR gene defects cause microsatellite instability (MSI-H), in which thousands of somatic mutations accumulate, allowing cancer cell proliferation together with immune evasion mechanisms (increased PD-L1 expression). From the molecular pathway perspective, constitutive activation of the RAS-MAPK pathway by FGFR3-activating mutations is central to low-grade papillary UTUC, whereas cell-cycle dysregulation due to loss of TP53 and RB1 drives high-grade invasive tumors. Because the urothelium is directly exposed to carcinogens in urine, a field effect across the whole urinary tract — in which the entire urinary tract (renal pelvis, ureter, bladder) is affected by carcinogens — explains the synchronous or metachronous occurrence of bladder cancer with UTUC.

6. Symptoms

The most common symptom of renal pelvic cancer is hematuria. Gross hematuria occurs in 75–80% and is often painless. Hematuria may appear intermittently and is sometimes mistaken as having resolved spontaneously. Upper urinary tract tumors must be ruled out in older men with recurrent intermittent hematuria.

Flank pain is the second most common symptom, occurring when blood clots from hematuria obstruct the ureter, causing hydronephrosis, or when the tumor itself obstructs the ureter. The pain may appear paroxysmally, like colicky pain. In advanced disease, systemic symptoms such as weight loss, fatigue and an abdominal mass may appear. Rarely, the tumor is asymptomatic and found incidentally on CT urography. Because Lynch syndrome–associated UTUC occurs at a relatively young age, family history investigation is important.

7. Signs

On physical examination, early UTUC often shows no specific findings. In advanced renal pelvic cancer, renal enlargement may be palpable or there may be costovertebral angle tenderness (CVA tenderness). On urinalysis, hematuria (microscopic or gross) is the key finding, and if hematuria persists on repeated testing, evaluation of the upper urinary tract is needed.

Malignant cells found on urine cytology strongly suggest urothelial carcinoma, which may originate in the upper urinary tract or the bladder. CT urography is the key imaging study evaluating the renal pelvis, ureters and bladder together, and a filling defect is the characteristic finding. Cystoscopy is performed to exclude bladder lesions in order to differentiate among multiple causes of hematuria. When there is a family history or associated cancers (colorectal cancer, endometrial cancer, etc.) suggesting possible Lynch syndrome, MMR protein immunohistochemistry is performed.

8. Screening

There is no standard screening program for renal pelvic cancer (UTUC) in the general population. However, because the lifetime risk of UTUC is very high in Lynch syndrome carriers, regular follow-up with annual urine cytology and CT urography every 2–3 years is recommended for carriers of MSH2 or MSH6 mutations. Detecting UTUC at an early stage in this way makes kidney-sparing treatment possible.

Regular urinalysis and CT urography follow-up are recommended for patients with a history of aristolochic acid exposure (long-term use of related herbal medicines, residence in the Balkans, etc.). Patients with a history of bladder cancer are at risk of upper tract recurrence or metachronous UTUC, so regular follow-up with CT urography is needed. Regular urinalysis in workers with occupational aromatic amine exposure contributes to early detection of UTUC and bladder cancer.

9. Diagnosis

The standard imaging study for diagnosing renal pelvic cancer is CT urography. Three-phase imaging — before contrast administration, in the parenchymal phase and in the excretory phase — evaluates all the transitional epithelium of the renal pelvis, ureters and bladder. A filling defect, mass or hydronephrosis within the renal pelvis are characteristic findings. MR urography is an alternative in patients who cannot receive iodinated contrast (renal failure, contrast allergy).

Ureteroscopy (URS) with tissue biopsy is key to the final diagnosis. Endoscopy allows direct visualization of the tumor within the renal pelvis, and tissue is obtained with biopsy forceps. Collecting selective urine cytology directly from the ureter increases diagnostic accuracy. FISH (fluorescence in situ hybridization)–based urine cytology (UroVysion) is more sensitive than conventional cytology and is particularly useful for diagnosing low-grade tumors. When tissue is obtained, MMR protein immunohistochemistry and FGFR3 mutation analysis are performed to screen for Lynch syndrome and to assess eligibility for FGFR inhibitors.

10. Treatment

The standard treatment for nonmetastatic UTUC is radical nephroureterectomy (RNU). This operation removes en bloc the ipsilateral kidney, the entire ureter and a bladder cuff including the ureteral orifice, and is performed open or laparoscopically/robot-assisted. Because recurrence in a residual ureteral stump is likely, removal of the entire ureter is essential. Lymphadenectomy is recommended, providing staging and a therapeutic benefit in some patients.

When a nephron-sparing approach is possible for low-grade, low-stage tumors: endoscopic resection via ureteroscopy (ureteroscopic laser resection) and percutaneous resection are considered in patients with a solitary kidney or impaired renal function. In these cases, because the risk of local recurrence is high, strict endoscopic follow-up is essential.

Preoperative neoadjuvant cisplatin-based chemotherapy is recommended for high-risk UTUC (high-grade, invasive). Postoperative adjuvant chemotherapy is also given for high-risk lesions. Erdafitinib (an FGFR inhibitor) has been approved for FGFR3 mutation–positive metastatic UTUC. Immune checkpoint inhibitors such as pembrolizumab are effective in MSI-H/Lynch syndrome–associated UTUC. For locally recurrent and metastatic UTUC, enfortumab vedotin + pembrolizumab or DDMVAC or GC (gemcitabine + cisplatin) chemotherapy is used.

11. Prognosis

Stage for stage, UTUC has a poorer prognosis than bladder cancer, because the thin muscle layer of the renal pelvis and ureter makes invasion easier.

Stage5-year cancer-specific survival
Ta/T1 (confined to mucosa/lamina propria)70–90%
T2 (invasion of muscle layer)50–70%
T3 (peripelvic/periureteral fat)30–50%
T4 / lymph node metastasis<10–20%

Aristolochic acid–associated UTUC tends to be multifocal and bilateral, so the risk of recurrence in the remaining kidney after surgery is high. Lynch syndrome–associated UTUC may respond excellently to immune checkpoint inhibitors owing to its MSI-H characteristics. Because intravesical recurrence occurs in 30–50% after UTUC surgery, regular cystoscopic follow-up is essential. Postoperative hydronephrosis, inpatient surgery, bilateral ureteral involvement and others are poor prognostic factors.

12. Prevention

In the prevention of renal pelvic cancer, smoking cessation is the most important single preventive measure. Smoking increases UTUC risk 2–7-fold, and quitting can reduce long-term risk. Banning herbal medicines containing aristolochic acid and educating patients about them are crucial for UTUC prevention in Asia, including Korea. In Korea, herbal medicines containing aristolochic acid (madouling, guanmutong, etc.) have been banned since 2005, but because awareness is still lacking in some cases, continued education is needed.

Reducing occupational aromatic amine exposure, wearing personal protective equipment and complying with workplace chemical exposure standards contribute to the prevention of urothelial carcinomas, including UTUC. Participation of Lynch syndrome carriers in regular surveillance programs is key to early detection of UTUC and improved treatment outcomes. Appropriate treatment of chronic urinary tract infections and management of urinary stones also have preventive significance. Adequate fluid intake (1.5 L or more per day) has an indirect preventive effect by diluting the concentration of carcinogens in urine and reducing exposure of the urothelium.


13. References

  1. Rouprêt M, et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma. Eur Urol. 2023;83(1):49–56.
  2. Margulis V, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer. 2009;115(6):1224–1233.
  3. Sfakianos JP, et al. Clinicopathological features of FGFR3-mutated upper tract urothelial carcinoma. Urol Oncol. 2022.
  4. Babjuk M, et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer. Eur Urol. 2022;81(1):75–94.
  5. Soria F, et al. Upper tract urothelial carcinoma in 2025: clinical guidelines, emerging therapies, and personalized care strategies. Urol Today. 2025.
  6. Huang CY, et al. Aristolochic acid nephropathy and urothelial malignancy associated with herbal medicines. Drug Saf. 2013;36(7):425–432.
  7. Lynch syndrome and upper tract urothelial carcinoma. Eur Urol. 2016;70(6):1024–1031.
  8. Korean Urological Association. Clinical practice guidelines for upper tract urothelial carcinoma. 2023.
  9. Powles T, et al. Pembrolizumab versus chemotherapy in advanced urothelial carcinoma (KEYNOTE-045). N Engl J Med. 2018;379(11):1011–1020.
  10. National Cancer Center. Safety information on aristolochic acid–related nephropathy and cancer. 2023.